Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Rani Therapeutics Holdings' Short term Debt history spans 6 years, with the latest figure at $13.5 million for Q3 2025.

  • On a quarterly basis, Short term Debt fell 8.34% to $13.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.5 million, a 8.34% decrease, with the full-year FY2024 number at $15.0 million, up 206.31% from a year prior.
  • Short term Debt came in at $13.5 million for Q3 2025, down from $15.0 million in the prior quarter.
  • The five-year high for Short term Debt was $15.0 million in Q4 2024, with the low at $30000.0 in Q2 2022.
  • Historically, Short term Debt has averaged $7.5 million across 5 years, with a median of $6.7 million in 2023.
  • Biggest five-year swings in Short term Debt: plummeted 99.23% in 2022 and later skyrocketed 2121.82% in 2023.
  • Year by year, Short term Debt stood at $126000.0 in 2021, then plummeted by 56.35% to $55000.0 in 2022, then soared by 8803.64% to $4.9 million in 2023, then soared by 206.31% to $15.0 million in 2024, then fell by 9.75% to $13.5 million in 2025.
  • Business Quant data shows Short term Debt for RANI at $13.5 million in Q3 2025, $15.0 million in Q2 2025, and $15.0 million in Q1 2025.